HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (7) Citing Articles via Google Scholar Google Scholar Articles by Bollerslev, J. Articles by Schreiner, T. Search for Related Content PubMed PubMed Citation Articles by Bollerslev, J. Articles by Schreiner, T.

Low-dose GH improves exercise capacity in adults with GH deficiency: effects of a 22-month placebo-controlled, crossover trial

Section of Endocrinology, The National Hospital, Oslo, Norway, ¹ The Norwegian University of Sport and PE, Oslo, Norway ² Medical Department, Section of Endocrinology, St Olav’s Hospital, Trondheim University Hospital, Trondheim, Norway, ³ Department of Endocrinology, Aker University Hospital, Oslo, Norway ⁴ Capturo AS, Kjeller, Norway ⁵ Scandinavian Clinical Research AS, Kjeller, Norway and the ⁶ Department of Endocrinology, University Hospital Malmø University Hospital, Malmø, Sweden

(Correspondence should be addressed to J Bollerslev, Section of Endocrinology, Department of Medicine, National University Hospital, N-0027 Oslo, Norway; Email: jens.bollerslev{at}klinmed.uio.no)

Fifty-five patients with adult-onset GH deficiency (mean age, 49 years) were enrolled in a placebo-controlled, crossover study to investigate the effects of GH therapy on exercise capacity, body composition, and quality of life (QOL). GH and placebo were administered for 9 months each, separated by a 4-month washout period. GH therapy was individually dosed to obtain an IGF-I concentration within the normal range for age and sex. The final mean daily dose of GH was 1.2 IU/day for men and 1.8 IU/day for women. Mean IGF-I concentration at baseline was higher in men than in women (95±33 vs 68±41 µg/l respectively; P < 0.04) and increased to a similar level on GH therapy. Body fat mass was reduced by 1.9±2.9 kg and lean body mass was increased by 1.8±2.8 kg (P = 0.0001 for each) with GH treatment. Total and low-density cholesterol levels decreased. Absolute maximal oxygen uptake increased by 6% (P = 0.01), relative to body weight by 9% (P = 0.004), and there was a trend toward increased endurance performance by 7% (P = 0.07). There were no significant effects on QOL. In conclusion, treatment with a low, physiologic dose of GH produced positive effects on body composition and lipids and improved exercise capacity, likely to be of clinical relevance. No changes in QOL were seen, possibly because of a good QOL at baseline.

This article has been cited by other articles:

				W. M. Widdowson and J. Gibney The Effect of Growth Hormone Replacement on Exercise Capacity in Patients with GH Deficiency: A Metaanalysis J. Clin. Endocrinol. Metab., November 1, 2008; 93(11): 4413 - 4417. [Abstract] [Full Text] [PDF]

				J. Gibney, M.-L. Healy, and P. H. Sonksen The Growth Hormone/Insulin-Like Growth Factor-I Axis in Exercise and Sport Endocr. Rev., October 1, 2007; 28(6): 603 - 624. [Abstract] [Full Text] [PDF]

				J. Bollerslev, S. Jansson, C. L. Mollerup, J. Nordenstrom, E. Lundgren, O. Torring, J.-E. Varhaug, M. Baranowski, S. Aanderud, C. Franco, et al. Medical Observation, Compared with Parathyroidectomy, for Asymptomatic Primary Hyperparathyroidism: A Prospective, Randomized Trial J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1687 - 1692. [Abstract] [Full Text] [PDF]

				J. Bollerslev, T. Ueland, A. P Jorgensen, K. J Fougner, R. Wergeland, T. Schreiner, and P. Burman Positive effects of a physiological dose of GH on markers of atherogenesis: a placebo-controlled study in patients with adult-onset GH deficiency. Eur. J. Endocrinol., April 1, 2006; 154(4): 537 - 543. [Abstract] [Full Text] [PDF]